{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:29Z","timestamp":1790179649208,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pcad.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:17:56Z","timestamp":1787325476000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank"],"prefix":"10.1016","author":[{"given":"Patrick","family":"Cheon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"McParland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi R.","family":"Rikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Petek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.pcad.2026.08.008_bb0005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2026.08.008_bb0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2026.08.008_bb0015","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.08.008_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.pcad.2026.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2026.08.008_bb0030","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology","author":"Mensah","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2026.08.008_bb0035","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"issue":"9822","key":"10.1016\/j.pcad.2026.08.008_bb0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcad.2026.08.008_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41525-019-0097-4","article-title":"A mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity","volume":"4","author":"Rosa","year":"2019","journal-title":"NPJ Genom Med"},{"issue":"3","key":"10.1016\/j.pcad.2026.08.008_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pcad.2026.08.008_bb0055","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2019.18","article-title":"Assessing atherosclerotic cardiovascular disease risk with advanced lipid testing: state of the science","volume":"15","author":"German","year":"2020","journal-title":"Eur Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2026.08.008_bb0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamacardio.2021.5080","article-title":"Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over","volume":"7","author":"Sniderman","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2026.08.008_bb0065","article-title":"Inflammation and lipid-related determinants in coronary atherosclerosis: mechanisms, biomarkers, and therapeutic implications","volume":"13","author":"Zhang","year":"2026","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.pcad.2026.08.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"7982","key":"10.1016\/j.pcad.2026.08.008_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pcad.2026.08.008_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2026.08.008_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.pcad.2026.08.008_bb0090","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.pcad.2026.08.008_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2026.08.008_bb0100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/dyr218","article-title":"Recommendations for presenting analyses of effect modification and interaction","volume":"41","author":"Knol","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.08.008_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12916-022-02446-6","article-title":"Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups","volume":"20","author":"Georgakis","year":"2022","journal-title":"BMC Med"},{"issue":"38","key":"10.1016\/j.pcad.2026.08.008_bb0110","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2026.08.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52572","article-title":"Dose-response associations of lipid traits with coronary artery disease and mortality","volume":"7","author":"Yang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2026.08.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf750","article-title":"Impact of LDL-C and apolipoprotein B level discordance and associated lipoprotein particle alterations on cardiovascular outcomes in a large primary prevention population","author":"Du","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2026.08.008_bb0125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:20:46Z","timestamp":1787426446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062026000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"alternative-id":["S0033062026000812"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2026.08.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}